Chiu Justin, Krupa Jordan M, Seah Claudia, Pasternak Stephen H
Department of Physiology and Pharmacology, The Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Robarts Research Institute, The Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Heliyon. 2024 May 11;10(10):e31077. doi: 10.1016/j.heliyon.2024.e31077. eCollection 2024 May 30.
The overproduction of the toxic peptide amyloid-beta (Aβ) generated from the cleavage of amyloid precursor protein (APP) is proposed to be a critical event in the development of Alzheimer's disease. Evidence suggests that the cleavage of APP occurs after its internalization from the cell surface. Previously, we identified a novel pathway for APP internalization, which trafficks cell surface APP directly to lysosomes by macropinocytosis, leading to its processing into Aβ. We also demonstrated that ADP-ribosylation factor 6 (Arf6) is required for the macropinocytosis of APP. Here, we characterized the roles of Arf6's downstream effectors Rac1, Cdc42 and RhoA. Both pharmacological inhibition and siRNA knockdown of these proteins reduced the amount of APP colocalized with LAMP1-labeled lysosomes without affecting APP transport to early endosomes. Decreases in the production of both Aβ40 and Aβ42 were also observed by ELISA in response to inhibitor treatment. These findings together demonstrate that Rac1, Cdc42 and RhoA are components of the mechanism regulating the macropinocytosis of APP and targeting these components can reduce the production of Aβ.
淀粉样前体蛋白(APP)裂解产生的毒性肽β-淀粉样蛋白(Aβ)过量生成被认为是阿尔茨海默病发展过程中的关键事件。有证据表明,APP的裂解发生在其从细胞表面内化之后。此前,我们鉴定了一条APP内化的新途径,该途径通过巨吞饮作用将细胞表面的APP直接运输到溶酶体,导致其加工成Aβ。我们还证明了ADP-核糖基化因子6(Arf6)是APP巨吞饮作用所必需的。在此,我们对Arf6的下游效应分子Rac1、Cdc42和RhoA的作用进行了表征。这些蛋白的药理学抑制和siRNA敲低均减少了与LAMP1标记的溶酶体共定位的APP量,而不影响APP向早期内体的转运。通过ELISA还观察到,响应抑制剂处理,Aβ40和Aβ42的产生均减少。这些发现共同表明,Rac1、Cdc42和RhoA是调节APP巨吞饮作用机制的组成部分,靶向这些组分可以减少Aβ的产生。